Tirzepatide news

All news on Tirzepatide (also known as Mounjaro): plants, production capacities, investments and involved companies.

6 November 2025
Lilly and U.S. Government Expand Access to Obesity Drugs
Medicare beneficiaries to access obesity drugs at $50/month. LillyDirect offers self-pay options. FDA approval pending.
6 November 2025
Lilly Expands Leadership Team for Growth
Lilly appoints Carole Ho and Adrienne Brown to Executive Committee, expands roles for Daniel Skovronsky and Jacob Van Naarden to drive growth in neuroscience and immunology.
30 October 2025
Lilly Q3 2025 Financials: Revenue Up 54%, R&D Progress, Guidance Raised
Revenue growth driven by incretin demand. Advanced orforglipron trials, FDA approval for Inluriyo. Expanded manufacturing in Virginia, Texas, Puerto Rico.
31 August 2025
Novo Nordisk: Wegovy® Reduces Heart Attack, Stroke, Death Risk by 57% vs. Tirzepatide
Wegovy® shows 57% greater risk reduction in heart events vs. tirzepatide in obese patients with CVD. Benefits are specific to semaglutide, not general to GLP-1 or GIP/GLP-1 classes.

Who will be producing Tirzepatide in the future?

Find out with chemXplore Analytics